Oxford BioDynamics (LSE:OBD) has unveiled a £7 million fundraising initiative through a placing and subscription of new ordinary shares. The capital raise is intended to support ongoing operations and accelerate business development opportunities.
The funds will enable the company to drive growth in sales of its PSE test, further develop its EpiSwitch KnowledgeBase in collaboration with Google Cloud, and advance third-party partnerships and collaborations. The fundraising is subject to shareholder approval at a general meeting. If the proposal is not approved, the company may be forced to explore alternative financing options or consider a potential sale.
Oxford BioDynamics’ outlook reflects substantial financial pressures, including ongoing net losses and negative cash flows. While technical analysis shows some short-term bullish signals, the valuation remains weak due to persistent profitability challenges. The lack of earnings call data and corporate events also limits further visibility.
More about Oxford BioDynamics
Oxford BioDynamics Plc is a precision clinical diagnostics company specializing in developing highly specific and sensitive tests for medical applications using its EpiSwitch 3D genomics platform. The company focuses on advancing personalized healthcare solutions and building strategic collaborations to strengthen its market presence.
Leave a Reply